AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6410897 — intervention group
Group type: COMPARATOR
Intervention: Unaltered milk (for 1 week)
Number of subjects: 79
Study 6410897 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidophilus milk (for 1 additional week)
Number of subjects: 79
Study 29960810 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (PR) group received a probiotic formulation containing Bifidobacterium breve BR03 and B. breve B632 for 3 months.
Number of subjects: 40
Study 29960810 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) group, received no active treatment.
Number of subjects: 40
Study 29960810 — intervention group
Group type: COMPARATOR
Intervention: Healthy Children (HC) group, sampled only once (T0).
Number of subjects: 40
Study 29342495 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIKES training with video reviews
Number of subjects: 61
Study 29342495 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 61
Study 27323614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusitis Mixture (SM)
Number of subjects: 50
Study 27323614 — intervention group
Group type: COMPARATOR
Intervention: Compound Sodium Chloride Injection (Control)
Number of subjects: 50
Study 25137874 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 to 320 mg/day (n = 18)
Number of subjects: 33
Study 25137874 — intervention group
Group type: COMPARATOR
Intervention: Non-renin-angiotensin-aldosterone-system blocking antihypertensive agents (control, n = 15)
Number of subjects: 33
Study 22447644 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing conservation intervention (not specified in detail)
Number of subjects: 392
Study 22447644 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of hearing protection and safety measures
Number of subjects: 392
Study 22447644 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of recreational and occupational noise sources, and chemical exposures with ototoxic potential
Number of subjects: 392
Study 20146169 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin, 20 mg daily
Number of subjects: 64
Study 20146169 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin, 20 mg daily
Number of subjects: 64
Study 17909315 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC boosted by bivalent gp120
Number of subjects: 130
Study 17909315 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC boosted by ogp160
Number of subjects: 130
Study 17909315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 17909315 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit-boosted vaccine
Number of subjects: 130
Study 17909315 — intervention group
Group type: EXPERIMENTAL
Intervention: ogp160-boosted vaccine
Number of subjects: 130
Study 17909315 — intervention group
Group type: EXPERIMENTAL
Intervention: gp120 B/E-boosted vaccine
Number of subjects: 130
Study 16184581 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg administered 30 min prior to sleep
Number of subjects: 15
Study 16184581 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered prior to sleep
Number of subjects: 15
Study 12100442 — intervention group
Group type: COMPARATOR
Intervention: CQ alone
Number of subjects: 153
Study 12100442 — intervention group
Group type: EXPERIMENTAL
Intervention: SP alone
Number of subjects: 153
Study 12100442 — intervention group
Group type: EXPERIMENTAL
Intervention: SP plus CQ
Number of subjects: 153
Study 12100442 — intervention group
Group type: EXPERIMENTAL
Intervention: SP plus PCM
Number of subjects: 153
Study 10421112 — intervention group
Group type: EXPERIMENTAL
Intervention: I ministernotomy
Number of subjects: 34
Study 10421112 — intervention group
Group type: COMPARATOR
Intervention: Full sternotomy
Number of subjects: 34
Study 8033770 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of cardiovascular risk factors in patients with mild to moderate hypertension
Number of subjects: 60
Study 3594304 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 burns
Number of subjects: 38
Study 3594304 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 burns
Number of subjects: 38
Study 3594304 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 burns
Number of subjects: 38
Study 30680649 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education by the teach-back method
Number of subjects: 50
Study 30680649 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study 28865152 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P) 300/120 mg once daily for 8 weeks (arm A)
Number of subjects: 136
Study 28865152 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir (400 mg once daily) + RBV (600-1000 mg weight-based, twice daily) for 12 weeks (arm B)
Number of subjects: 136
Study 28865152 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P) for 12 weeks in CERTAIN-1 study
Number of subjects: 136
Study 26859236 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT
Number of subjects: 60
Study 26859236 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT + AET
Number of subjects: 60
Study 26859236 — intervention group
Group type: EXPERIMENTAL
Intervention: AET
Number of subjects: 60
Study 24793735 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial symmetry
Number of subjects: 64
Study 24793735 — intervention group
Group type: EXPERIMENTAL
Intervention: Feminine versions of faces
Number of subjects: 64
Study 24793735 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial non-averageness (distinctiveness)
Number of subjects: 64
Study 22677762 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of insulin
Number of subjects: 47
Study 22677762 — intervention group
Group type: COMPARATOR
Intervention: Frequent (every 3h) subcutaneous injections of insulin
Number of subjects: 47
Study 20653168 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus blood-letting by a three-edged needle
Number of subjects: 100
Study 20653168 — intervention group
Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 100
Study 18612727 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive spaced-education (ISE) program, 18-week duration, 6 e-mails per week for 6 weeks, repeated for 2 additional cycles.
Number of subjects: 120
Study 18612727 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive spaced-education (ISE) program
Number of subjects: 120
Study 18612727 — intervention group
Group type: COMPARATOR
Intervention: Control group (Cohort B)
Number of subjects: 120
Study 15901972 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone alone
Number of subjects: 18
Study 15901972 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus fusidic acid
Number of subjects: 18
Study 11817991 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment with concomitant benazepril therapy
Number of subjects: 0
Study 11817991 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive treatment without benazepril
Number of subjects: 0
Study 10756613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention in eight practices for one year (September 1996 to August 1997) at a cost of 163,000 Pounds.
Number of subjects: 16
Study 10756613 — intervention group
Group type: COMPARATOR
Intervention: Control group (eight matched practices without pharmacist intervention).
Number of subjects: 16
Study 8785399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA; 4 to 5 mg/kg per day)
Number of subjects: 41
Study 8785399 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 to 30 mg daily)
Number of subjects: 41
Study 1809708 — intervention group
Group type: EXPERIMENTAL
Intervention: Low viscosity bone cement
Number of subjects: 41
Study 1809708 — intervention group
Group type: COMPARATOR
Intervention: High viscosity bone cement
Number of subjects: 41
Study 6219689 — intervention group
Group type: EXPERIMENTAL
Intervention: I% metronidazole cream
Number of subjects: 81
Study 6219689 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cream base)
Number of subjects: 81
Study 30786974 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical bypass (OSB)
Number of subjects: 311
Study 30786974 — intervention group
Group type: COMPARATOR
Intervention: Plain balloon angioplasty (PBA)
Number of subjects: 311
Study 29121350 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized FSH dosing (450/225 IU for RCT1, 100 IU for RCT2)
Number of subjects: 1515
Study 29121350 — intervention group
Group type: COMPARATOR
Intervention: Standard FSH dosing (150 IU)
Number of subjects: 1515
Study 29121350 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized FSH dosing
Number of subjects: 1515
Study 25639994 — intervention group
Group type: EXPERIMENTAL
Intervention: STEP (Specialized Treatment Early in Psychosis)
Number of subjects: 120
Study 25639994 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 120
Study 24565591 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (Group I, n = 23)
Number of subjects: 48
Study 24565591 — intervention group
Group type: COMPARATOR
Intervention: Standard percutaneous coronary intervention without preconditioning (Group II, n = 25)
Number of subjects: 48
Study 22580981 — intervention group
Group type: EXPERIMENTAL
Intervention: Kettlebell swing training (KB)
Number of subjects: 21
Study 22580981 — intervention group
Group type: COMPARATOR
Intervention: Jump squat power training (JS)
Number of subjects: 21
Study 19570621 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed reward discounting (DRD) for money
Number of subjects: 57
Study 19570621 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline discounting
Number of subjects: 57
Study 17690015 — intervention group
Group type: EXPERIMENTAL
Intervention: TrP anesthetic infiltration (group 1) on the 3rd, 10th, 30th, and 60th day after threshold measurement.
Number of subjects: 78
Study 17690015 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group 2).
Number of subjects: 78
Study 17690015 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control group).
Number of subjects: 78
Study 15247107 — intervention group
Group type: EXPERIMENTAL
Intervention: Open lung concept (OLC)
Number of subjects: 24
Study 15247107 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 24
Study 21901907 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU of vitamin A
Number of subjects: 404
Study 21901907 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU of vitamin A
Number of subjects: 404
Study 21901907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both supplemented groups (200,000 IU and 50,000 IU)
Number of subjects: 404
Study 9829646 — intervention group
Group type: COMPARATOR
Intervention: 500 lx light
Number of subjects: 34
Study 9829646 — intervention group
Group type: COMPARATOR
Intervention: Dark
Number of subjects: 34
Study 9829646 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 10 mg
Number of subjects: 34
Study 9829646 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 34
Study 9829646 — intervention group
Group type: COMPARATOR
Intervention: Dim light (20-30 lx)
Number of subjects: 34
Study 9829646 — intervention group
Group type: COMPARATOR
Intervention: Varying light intensities (300 to 2000 lx)
Number of subjects: 34
Study 7860686 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic totally pre-peritoneal hernia repair
Number of subjects: 241
Study 7860686 — intervention group
Group type: COMPARATOR
Intervention: Shouldice technique
Number of subjects: 241
Study 2347652 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 administered as a single intravenous bolus of 2400 anti‐Xa units at start of dialysis
Number of subjects: 36
Study 2347652 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 administered as a single bolus of 3200 anti‐Xa units at start of dialysis
Number of subjects: 36
Study 2347652 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin (3250‐4750 I.U. heparin at start of hemodialysis followed by continuous infusion of 2000‐2700 I.U. per hour)
Number of subjects: 36
Study 2347652 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including Org 10172 and heparin)
Number of subjects: 36
Study 2347652 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 36
Study 2347652 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36
Study 2347652 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172
Number of subjects: 36
Study 486891 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of 60 ml of sodium iothalamate 70%
Number of subjects: 0
Study 486891 — intervention group
Group type: COMPARATOR
Intervention: Infusion of a larger dose of contrast agent
Number of subjects: 0
Study 31964564 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-located contraceptive services at well-baby visits
Number of subjects: 446
Study 31964564 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 446
Study 31964564 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-located contraceptive services at well-baby visits (for those who accepted the visit)
Number of subjects: 446
Study 29886416 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger habit (associated with higher nebuliser adherence)
Number of subjects: 61
Study 28011757 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (up to 2.5 mg three times daily)
Number of subjects: 261
Study 25453380 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen Hoodia (3 g)
Number of subjects: 0
Study 25453380 — intervention group
Group type: COMPARATOR
Intervention: Placebo cubes
Number of subjects: 0
Study 24879965 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (TG) - weight-lifting exercises for 6 muscle groups (2 sets of 8 repetitions at 80% of 1-repetition maximum)
Number of subjects: 46
Study 24879965 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 46
Study 24879965 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (TG)
Number of subjects: 46
Study 21568628 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 274
Study 21568628 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 274
Study 19770322 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioguided localization
Number of subjects: 134
Study 19770322 — intervention group
Group type: COMPARATOR
Intervention: Wire localization
Number of subjects: 134
Study 17561009 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone 50 microg/day + 17beta-estradiol 350 microg/day
Number of subjects: 333
Study 17561009 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone 175 microg/day + 17beta-estradiol 350 microg/day
Number of subjects: 333
Study 17561009 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone 550 microg/day + 17beta-estradiol 350 microg/day
Number of subjects: 333
Study 17561009 — intervention group
Group type: COMPARATOR
Intervention: Oral norethisterone acetate 1 mg/day + 17beta-estradiol 2 mg/day
Number of subjects: 333
Study 17561009 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 333
Study 15709712 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic irradiated RCC-cell-line cells (ACHN-IL-2) admixed with autologous metastatic formalin-treated tumour cells, administered subcutaneously, 4-20 injections (mean 10 +/- 4), average of 92 x 10(6) ACHN-IL-2 transfected cells.
Number of subjects: 30
Study 15709712 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard immunotherapy without the vaccine.
Number of subjects: 30
Study 11795345 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 9732298 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary γ-linolenic acid (GLA)
Number of subjects: 0
Study 8273793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg/day continuously for 5 years (Group A)
Number of subjects: 80
Study 8273793 — intervention group
Group type: COMPARATOR
Intervention: Seasonal prophylactic treatment with ranitidine 300 mg/day for 8 weeks in spring and fall (Group B)
Number of subjects: 80
Study 3054641 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (11 patients)
Number of subjects: 74
Study 3054641 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) - one swallow tablet 4 times a day (11 patients)
Number of subjects: 74
Study 3054641 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) - two swallow tablets twice daily (16 patients)
Number of subjects: 74
Study 3054641 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) - two buffered swallow tablets twice daily (14 patients)
Number of subjects: 74
Study 3054641 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) - two chew tablets twice daily (22 patients)
Number of subjects: 74
Study 3054641 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients cleared of C pylori
Number of subjects: 74
Study 3054641 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients rebiopsied 44‐137 days following treatment
Number of subjects: 74
Study 31640804 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone addiction (average score 73.77±11.48 for boys, 74.64±12.28 for girls)
Number of subjects: 439
Study 31640804 — intervention group
Group type: EXPERIMENTAL
Intervention: Sense of loneliness (average score 43.22±5.16 for boys, 42.82±5.30 for girls)
Number of subjects: 439
Study 31640804 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between mobile phone addiction and sense of loneliness
Number of subjects: 439
Study 28319586 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 37
Study 28319586 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 37
Study 25742531 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace psychosocial intervention
Number of subjects: 1630
Study 25742531 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1630
Study 23922092 — intervention group
Group type: EXPERIMENTAL
Intervention: Repositioning of routine management
Number of subjects: 90
Study 23922092 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 90
Study 23922092 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam dressing
Number of subjects: 90
Study 23922092 — intervention group
Group type: COMPARATOR
Intervention: Gender, hypertension history, and BMI
Number of subjects: 90
Study 21892573 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet (LGI)
Number of subjects: 12
Study 21892573 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic index diet (HGI)
Number of subjects: 12
Study 19954715 — intervention group
Group type: EXPERIMENTAL
Intervention: Equasym Retard 20 mg
Number of subjects: 14
Study 19954715 — intervention group
Group type: COMPARATOR
Intervention: Medikinet retard 20 mg
Number of subjects: 14
Study 17406138 — intervention group
Group type: EXPERIMENTAL
Intervention: Enuretic alarm therapy (group 1)
Number of subjects: 103
Study 17406138 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin therapy (group 2)
Number of subjects: 103
Study 17406138 — intervention group
Group type: EXPERIMENTAL
Intervention: Enuretic alarm therapy as secondary treatment (group 3)
Number of subjects: 103
Study 14993506 — intervention group
Group type: EXPERIMENTAL
Intervention: High dialysis dose (HDD) group (target Kt/V(eq) of 1.4)
Number of subjects: 50
Study 14993506 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein (HP) diet (1.3 g/kg of ideal body weight/day)
Number of subjects: 50
Study 14993506 — intervention group
Group type: COMPARATOR
Intervention: Regular protein (RP) diet (0.9 g/kg/day)
Number of subjects: 50
Study 14993506 — intervention group
Group type: EXPERIMENTAL
Intervention: High dialysis dose (HDD) group
Number of subjects: 50
Study 14993506 — intervention group
Group type: COMPARATOR
Intervention: Regular dialysis dose (RDD) group
Number of subjects: 50
Study 14993506 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein (HP) diet
Number of subjects: 50
Study 14993506 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing dialysis dose
Number of subjects: 50
Study 11563997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 24
Study 11563997 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 10 mg
Number of subjects: 24
Study 11563997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9258137 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg oral desmopressin
Number of subjects: 141
Study 9258137 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mcg oral desmopressin
Number of subjects: 141
Study 9258137 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mcg oral desmopressin
Number of subjects: 141
Study 9258137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 8416326 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual estimates before PTCA
Number of subjects: 305
Study 8416326 — intervention group
Group type: COMPARATOR
Intervention: Quantitative angiography before PTCA
Number of subjects: 305
Study 8416326 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual estimates immediately after PTCA
Number of subjects: 305
Study 8416326 — intervention group
Group type: COMPARATOR
Intervention: Quantitative angiography immediately after PTCA
Number of subjects: 305
Study 8416326 — intervention group
Group type: COMPARATOR
Intervention: Quantitative measurements at follow-up
Number of subjects: 305
Study 8416326 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual estimates at follow-up
Number of subjects: 305
Study 2944924 — intervention group
Group type: EXPERIMENTAL
Intervention: nortriptyline or phenelzine
Number of subjects: 72
Study 2944924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 29117738 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency transcutaneous electrical nerve stimulation (TENS) plus semi-supervised exercise for 35 minutes a day for 20 sessions (4 weeks)
Number of subjects: 70